Cogent Biosciences, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2017 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Cogent Biosciences, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2017 to Q4 2023.
  • Cogent Biosciences, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $157M, a 75.4% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $157M +$67.5M +75.4% Dec 31, 2023 10-K 2024-02-26
Q4 2022 $89.5M +$42.9M +91.8% Dec 31, 2022 10-K 2024-02-26
Q4 2021 $46.7M +$18.9M +67.9% Dec 31, 2021 10-K 2023-03-14
Q4 2020 $27.8M -$10.7M -27.8% Dec 31, 2020 10-K 2022-03-15
Q4 2019 $38.5M +$9.59M +33.2% Dec 31, 2019 10-K 2021-03-16
Q4 2018 $28.9M +$12.3M +74% Dec 31, 2018 10-K 2020-03-26
Q4 2017 $16.6M Dec 31, 2017 10-K 2019-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.